Predictive Oncology FY2024 loss $10.8M on $1.6M revenue; cash drops to $0.7M; merger with Renovaro pending

Axe Compute Inc.

Revenue of $1.6M essentially flat YoY; loss from continuing ops of $10.8M.
Cash and equivalents fell to $734,673 from $8.7M; stockholder deficit of ($202,610).
Net loss per share from continuing ops improved 33% to $1.99.
Raised $3M in early 2025 via asset sale, warrant exercises, and Renovaro financing.
Still working toward definitive merger agreement with Renovaro after Jan LOI.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.